BIOVAXYS TECHNOLOGY CORP - BVAXF STOCK NEWS

BioVaxys Technology Corp. (OTCQB: BVAXF) announced the acquisition of TAETSoftware Corp, a Vancouver-based clinical studies management company. The deal involved issuing 24.5 million common shares, with an additional 2.5 million shares contingent on successful beta testing of the Trial Adverse Events Tracker (TAET) platform. This innovative application allows real-time reporting of adverse drug events in clinical trials, improving data accuracy and responsiveness. Additionally, BioVaxys completed a private placement, raising $670,000 through the issuance of 5.36 million shares. The company aims to utilize these funds for working capital and will leverage TAET to enhance revenue opportunities in the clinical study sector.

BioVaxys Technology Corp. has finalized a US Distribution Agreement with Procare Health Iberia for Papilocare® and Oral Immunocaps©. Papilocare® is a patented vaginal gel for preventing and treating HPV-related cervical lesions, with proven efficacy in clinical trials. BioVaxys will pursue FDA approval for Papilocare®, while Immunocaps© can be marketed without regulatory hurdles. The agreement also includes future discussions on other Procare products for women's health. This collaboration aims to expand access to innovative treatments for cervical health in the US market.

BioVaxys Technology Corp. (OTCQB: BVAXF) announces that Co-Founder, President & COO Kenneth Kovan will present at the MedInvest Oncology Investor Conference in New York City on December 14-15, 2022. This event, in partnership with the National Foundation for Cancer Research, gathers oncology-focused investors and companies. Kovan, with over 30 years of biopharma experience, will discuss BioVaxys' haptenized protein platform for cancer immunotherapies, including developments for ovarian cancer. The conference features industry leaders and is supported by the National Cancer Institute.

BioVaxys Technology Corp. has successfully completed a sterile test-run production of its BVX-0918 ovarian cancer vaccine, validating the production protocols developed over recent months. This involved extracting tumor cells from a cancer patient and significantly reducing production time by 50%. The company now aims to optimize the vaccine production process and prepare for regulatory submission in the EU. BioVaxys is advancing its clinical studies with Procare Health Iberia for a Phase I trial, marking a significant milestone in their cancer vaccine development.

BioVaxys Technology Corp. has signed a binding agreement with Procare Health for the exclusive marketing and distribution of their HPV treatment product, Papilocare, and the immune-support supplement Immunocaps in the US. This agreement grants BioVaxys a right of first refusal for Procare's other products, Ovosicare and Libicare. BioVaxys anticipates rapid revenue generation from Immunocaps, which does not require FDA approval. The partnership also involves milestone payments and royalties. Regulatory approval for Papilocare as a Class II medical device is expected.

BioVaxys Technology Corp. announced the expansion of its intellectual property portfolio by filing an international patent application via the Patent Cooperation Treaty for BVX-1021, a vaccine targeting SARS-CoV-1 and other sarbecoviruses. Additionally, the company has filed multiple National Phase patent applications for BVX-0320, a SARS-CoV-2 S1 subunit vaccine, across key pharmaceutical markets including the US and EU. This strategic move aims to enhance patent protection and bolster its position in the biotechnology sector.

BioVaxys Technology Corp. has successfully closed the first tranche of its non-brokered private placement, securing gross proceeds of $200,000 from the issuance of 2,000,000 units at $0.10 each. Each unit includes one common share and one warrant, exercisable at $0.20 for 48 months. This private placement aims to raise up to $1,000,000 with the second tranche expected to close soon. Funds will be utilized for working capital, and all securities issued will be subject to a statutory hold period.

BioVaxys Technology Corp. announced a significant milestone in the development of its ovarian cancer vaccine, BVX-0918. The first tumors were surgically excised from patients and sent to BioVaxys for manufacturing process validation. Collaborations with Hospices Civils de Lyon and Deaconess Research Institute facilitate tumor sourcing for production. The vaccine relies on a process of haptenization to enhance immune recognition of cancer cells. Previous clinical trials using a first-generation vaccine demonstrated promising overall survival rates. BioVaxys aims to complete Good Manufacturing Process (GMP) production soon.

BioVaxys Technology Corp. has announced that its partner, BioElpida, has successfully created multiple OVCAR-3 cell banks, essential for the GMP manufacturing of BVX-0918, a vaccine aimed at treating platinum-resistant ovarian cancer. This step is crucial for regulatory compliance in both the EU and the US, with a Phase I study planned for later this year. The company is also collaborating with medical institutions to validate tumor collection protocols for bioproduction. The innovative vaccine platform utilizes haptenization to enhance immune response against cancer cells.